This reference evaluates and describes the latest strategies for hormone suppression and blockade in the management of early and advanced stage breast cancer and explores the effects of tamoxifen, selective estrogen receptor modulators (SERMs), aromatase inhibitors, and their combination on both breast cancers and normal tissues. Endocrine Therapy in Breast Cancer ·details modern techniques for molecular profiling, monitoring, and targeting ·offers methods to identify high-risk groups ·evaluates molecular biomarkers in breast cancer assessment ·examines the potential toxicity of estrogen receptor (ER)-directed endocrine therapy ·investigates the development of endocrine resistance ·discusses neoadjuvant and preoperative approaches in patient care ·reviews mechanisms that lead to estrogen-independent phenotypes Surveying the medical, surgical, and pathological aspects of endocrine therapy, as well as future research opportunities, Endocrine Therapy in Breast Cancer is a concise and in-depth manual for medical, surgical, and radiation oncologists; endocrinologists; gynecologists; obstetricians; pharmacologists; family physicians; reproductive biologists; epidemiologists; and medical school students.
Author(s): MIller Ingle
Edition: 1
Year: 2002
Language: English
Pages: 400
Preface......Page 5
Contents......Page 9
Contributors......Page 13
Why Endocrine Therapy?......Page 19
Tamoxifen and Advanced Breast Cancer: An Overview......Page 33
Overview of Aromatase Inhibitors and Inactivators in the Treatment of Advanced Breast Cancer......Page 49
Endocrine Treatment of Advanced Breast Cancer: Selective Estrogen-Receptor Modulators (SERMs)......Page 63
Other Endocrine and Biological Agents in the Treatment of Advanced Breast Cancer......Page 95
Early Breast Cancer: Tamoxifen Overview......Page 141
Aromatase Inhibitors and Early Breast Cancer......Page 151
SERMs: Overview in Early Breast Cancer......Page 161
Surrogate and Intermediate Markers in Early Breast Cancer......Page 173
Neoadjuvant Endocrine Therapy for Breast Cancer: A Medical Oncologist’s Perspective......Page 197
Neoadjuvant Therapy: Surgical Perspectives......Page 213
Pathology of Breast Cancer Following Neoadjuvant Endocrine Therapy......Page 229
Neoadjuvant Therapy: Prediction of Response......Page 239
Mechanisms of Resistance to Endocrine Therapy......Page 247
Epidemiological Basis of Hormonal Chemoprevention of Breast Cancer......Page 283
Breast Carcinogenesis and Its Prevention by Inhibition of Estrogen Genotoxicity......Page 303
Use of Selective Antiestrogens for the Chemoprevention of Breast Cancer......Page 319
Aromatase Inhibitors and Chemoprevention of Breast Cancer......Page 325
Index......Page 381
